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summary
The aim of the study was to evaluate atherosclerosis in ankylosing spondylitis (AS) through the assessment of 
morphological and functional measures of subclinical atherosclerosis.
Twenty patients [M/F=12/8, age (median/range) 43.5/28-69 years; disease duration (median/range) 9.7/1-36) 
years] with AS classified according to modified New York criteria and twenty age and sex related healthy 
controls with negative past medical history for cardiovascular events were enrolled in the study. In all patients 
and controls, the intima-media thickness (IMT) of common carotid artery, carotid bulb and internal carotid 
artery, and the flow-mediated dilatation (FMD) of non-dominant arm brachial artery were determined, us-
ing a sonographic probe Esaote GPX (Genoa, Italy). Furthermore, we assess the main disease activity and 
disability indices [bath ankylosing spondylitis disease activity index, ankylosing spondylitis disease activity 
score-eritrosedimentation rate (ASDAS-ESR), ASDAS-C-reactive protein (CRP), bath ankylosing spondylitis 
metrology index, bath ankylosing spondylitis functional index) and acute phase reactants. Plasmatic values of 
total cholesterol, low-density lipoprotein, high-density lipoprotein, triglyceride and homocysteine were carried 
out in all twenty patients.
IMT at carotid bulb was significant higher in patients than in controls (0.67 mm vs 0.54 mm; P=0.03). FMD did 
not statistically differ between patients and controls (12.5% vs 15%; P>0.05). We found a correlation between 
IMT at carotid bulb and ESR (rho 0.43; P=0.04). No correlation was found between FMD and disease activity 
and disability indices.
This study showed that in AS patients, without risk factors for cardiovascular disease, carotid bulb IMT, mor-
phological index of subclinical atherosclerosis, is higher than in controls. 
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n	 INTRODUCTION 
Ankylosing spondylitis (AS) is a chron-ic systemic inflammatory disease that 
predominantly affects axial skeleton, with 
a possible peripheral and extra-articular in-
volvement. AS patients have an increased 
mortality in respect to the general popula-
tion (1), due to approximately 40% of car-
diovascular disease cases, representing the 
leading cause of death (2). Several studies 
demonstrated the presence of an acceler-
ated atherosclerotic process and increased 
cardiovascular morbidity and mortality in 
patients with chronic rheumatic diseases 
(3-5). In fact, it has been estimated that the 
relative risk of developing atherosclerotic 
disease is 3 in rheumatoid arthritis (3), 4-8 
in systemic lupus erythematosus (6) and 
1.2-1.8 in AS (7) compared to the general 
population. The link between inflamma-
tion and atherosclerosis is supported by 
observational studies performed on a large 
series of patients. These studies showed 
a close correlation between serum levels 
of acute phase reactants, in particular C-
reactive protein (CRP), and an increased 
risk of acute myocardial infarction, stroke 
and peripheral vascular disease. Also, 
CRP in long-standing rheumatoid arthri-
tis patients correlated with the presence 
of subclinical atherosclerosis. Likewise, 
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chronic inflammation determined by CRP 
levels over an extended follow-up was also 
found to be associated with the develop-
ment of cardiovascular events and cardio-
vascular mortality in rheumatoid arthritis 
(3, 6, 8-11). The expression of cytokines 
and pro-inflammatory mediators plays a 
crucial role in all phases of atherosclerotic 
process in patients with rheumatic diseases 
(12). The presence of subclinical athero-
sclerosis could be detected by non-invasive 
ultrasonographic tools, through the assess-
ment of carotid intima-media thickness 
(IMT) (13-15) and flow-mediated dilata-
tion (FMD) (16, 17). Both methods are 
closely related to endothelial damage and 
dysfunction, early markers of atheroscle-
rosis (18, 19). Prospective and retrospec-
tive studies showed that the assessment 
of endothelial function and arterial wall 
morphology could be useful in identifying 
patients at high risk of atherosclerosis and 
to predict the risk of developing cardiovas-
cular events (19-21). Recently, it has been 
demonstrated that patients with rheuma-
toid arthritis and psoriatic arthritis have an 
increased IMT of carotid wall and abnor-
malities of FMD (22-26). The prevalence 
of increased subclinical atherosclerosis has 
been studied in AS through the assessment 
of IMT and FMD, but the presence of posi-
tive or negative history for cardiovascular 
risk factors, cardiovascular events or con-
comitant medications, have led to ambigu-
ous results (27-32). Furthermore, in the 
assessment of carotid IMT, it was not con-
sidered the evaluation of different arterial 
segments (common carotid artery, internal 
carotid artery and bulb), characterized by 
a different progression of atherosclerotic 
process (33, 34). Finally IMT and FMD 
were analyzed in the same patients only in 
few studies (27, 31) and the correlations of 
these indices of subclinical atherosclerosis 
with the disease activity or disability indi-
ces must be better defined. 
The aim of the present study is to inves-
tigate segmental carotid IMT and brachial 
arterial FMD in AS patients without car-
diovascular risk factors and their possible 
correlation with disease activity and dis-
ability indices.
n	 MATERIALS AND METHODS
Twenty patients (M/F=12/8) with AS, clas-
sified according to modified New York 
criteria (35), and 20 healthy controls were 
enrolled. Subject’s written consent was 
obtained according to the declaration of 
Helsinki, and the design of the work has 
been approved by local ethical committee. 
Exclusion criteria were: clinical history of 
hypertension; angina pectoris; ischemic 
heart disease; cerebrovascular events; 
transient ischemic attack; peripheral arte-
rial disease; dyslipidaemia; diabetes mel-
litus. All patients and controls currently 
are non-smokers. AS patients in treatment, 
past or present, with TNFα inhibitors were 
excluded. In all AS patients the evaluation 
of the bath ankylosing spondylitis disease 
activity index (BASDAI) (36), ankylosing 
spondylitis disease activity score (ASDAS) 
(37), bath ankylosing spondylitis metrol-
ogy index (BASMI) (38), bath ankylosing 
spondylitis functional index (BASFI) (39), 
eritrosedimentation rate (ESR), CRP, total 
cholesterol, low density lipoprotein (LDL), 
high density lipoprotein (HDL), triglycer-
ide and homocysteine were performed. 
The presence of subclinical atherosclerosis 
was assessed analyzing carotid IMT and 
FMD of brachial artery by high-resolution 
B-mode ultrasound (US) examination using 
Esaote GPX (Genoa, Italy), equipped with 
linear probe (7-10 MHz), by an operator 
who was blinded to all clinical information.
Carotid intima-media thickness
Scanning was performed on the patient’s 
carotid arteries in the supine position with 
the neck extended. The probe was placed 
in the longitudinal plane at the anterolat-
eral position of the right side of the neck 
then followed by the left side of the neck. 
The measurement of carotid artery IMT 
was obtained at three sites: 1 cm distally 
to carotid bulb in common carotid artery 
(CCA), at carotid bulb (BULB), and 1 cm 
proximally to carotid bulb in the internal 
carotid artery (ICA) (Fig. 1). IMT was 
measured in the anterior and posterior wall 
of artery. The mean thickness (IMTm) at 
each site was recorded at the three sections 
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bilaterally, after freezing the image on each 
occasion. IMT was defined as the distance 
between the inner echogenic line represent-
ing the intima-blood interface and the outer 
echogenic line representing the adventitia 
media junction. It was measured along the 
near and far wall of carotid artery. Further-
more, carotid bulb was defined as the point 
where the far wall deviated away from the 
parallel plane of the distal common carotid 
artery. Pathological IMT was defined as 
IMTm greater than 0.9 mm (40). 
Flow-mediated dilatation of brachial ar-
tery
Evaluation of FMD was obtained by longi-
tudinal B-mode US scan of the brachial ar-
tery, approximately 5 cm above the elbow 
of the non-dominant arm. The evaluation 
of the arteriolar diameter was performed 
at baseline and after hyperemia induced by 
applying sphygmomanometer inflated to a 
pressure of about 50 mmHg higher than the 
systolic blood pressure for 5 min. The ar-
teriolar diameter after induced hyperemia 
was obtained at 30s, 60s, 90s and 120s, 
synchronizing the measurements with the 
R-wave electrocardiogram.
We calculated FMD as the maximum per-
centage increase (FMD%) and as maximal 
difference (ΔFMD) of brachial artery diam-
eter after induced hyperemia in comparison 
with baseline. All measurements were per-
formed in a temperature controlled room, 
with the patient fasted for at least 12 h. All 
medications, caffeine intake or smoke were 
discontinued at least 24 hours prior to the 
exam.
Statistical analysis
Categorical variables were analyzed by 
χ-square test or Fisher’s exact test. Con-
tinuous variables were analyzed by Mann-
Whitney test for unpaired data or Wilcoxon 
test for paired data. The significance of cor-
relations was determined using the Spear-
man’s rank correlation coefficient. The 
results were presented as median (25th-75th 
percentile). P values less than 0.05 were 
considered significant.
n	 RESULTS
Anthropometric, clinical and laboratory 
features of study population are shown in 
Table I - Anthropometric, clinical and laboratory 
characteristics in ankylosing spondylitis patients 
(n=20).
Male/female 12/8
Age (years) 43.5 (28-69)**
Disease duration (years) 9.7 (1-36)**
ESR (mm/Ia h) 14/4-35*
CRP (mg/dL) 1.4/0.1-3.4*
Homocysteinemia (ng/dL) 11.0/7.8-12.5*
Total cholesterol (mg/dL) 175.0/153.5-207.5*
 LDL (mg/dL) 101.5/86.0-132.0*
 HDL (mg/dL) 48.0/40.5-62.5*
Triglycerides (mg/dL) 69/53-106*
BMI 22.25/20.60-26.45*
Mean blood pressure (mmHg) 103/97-113*
BASDAI 4.22/2.36-6.01*
BASMI 3/0.5-7.5*
BASFI 4.75/2.18-8.30*
ASDAS-ESR 3.15/1.375-4.025*
ASDAS-CRP 3.25/1.45-3.95*
HLA-B27 + 75%
Extra-articular manifestation 20%
NSAIDs 
COXib 
Analgesic 
No treatment 
30%
30%
10%
30%
ESR, eritrosedimentation rate; CRP, C-reactive 
protein; LDL, low-density lipoprotein; HDL, high-
density lipoprotein; BMI, body mass index; BAS-
DAI, bath ankylosing spondylitis disease activity 
index; BASMI, bath ankylosing spondylitis metrol-
ogy index; BASFI, bath ankylosing spondylitis 
functional index; ASDAS, ankylosing spondylitis 
disease activity score; NSAIDs, non steroidal anti-
inflammatory drugs; COXib, cyclooxygenase type 
2. *median/25th-75th percentile; **median (range).
Figure 1 - Ultrasound imaging of right carotid 
artery and its segments: common carotid ar-
tery (CCA), carotid bulb (BULB), internal ca-
rotid artery (ICA).
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and FMD values (median/25th-75th percen-
tile) of AS patients and healthy controls are 
reported in Table II. IMT values at BULB 
were significantly higher in patients than in 
controls (P=0.03) (Fig. 2). No statistically 
difference was found in IMT values at CCA 
and ICA segments. No patients or controls 
had IMT values greater than 0.9 mm. The 
assessment of FMD showed no significant 
differences between two groups. No corre-
lation was found between IMT and FMD 
values (rho=0.15). 
The correlations between clinical and labo-
ratory indices and US markers of subclini-
cal atherosclerosis are shown in Table III. 
In AS patients, the only significant correla-
tion was found between BULB IMT with 
ESR values (rho 0.43; P=0.04). No statisti-
cally significant correlation was found be-
tween IMT and FMD values with disease 
duration. Finally, there were statistically 
significant inverse correlations between 
plasma HDL values with BASDAI (rho 
-0.45; P=0.046) and CRP levels (-0.47: 
P=0.03).
Figure 2 - Mean intima-media thickness (IMTm) values (box and 
whiskers plot: median/25th-75th percentile/range) at carotid bulb in 
ankylosing spondylitis patients (n=20) and controls (n=20) (p=0.03).
Table II - Mean intima-media thickness and flow-mediated dilatation values (median/25th-75th percentile) 
in ankylosing spondylitis patients (n=20) and healthy controls (n=20)
as
(n=20)
Controls
(n=20)
P value
CCA IMTm (mm) 0.6/0.523-0.700 0.56/0.50-0.70 n.s.
BULB IMTm (mm) 0.67/0.580-0.805 0.54/0.49-0.6 0.03
ICA IMTm (mm) 0.515/0.500-0.645 0.53/0.500-0.66 n.s.
ΔFMD (mm) 4.4/3.80-4.90 4.60/3.70-5.90 n.s.
FMD% 12.5/9.45-17.35 15/12-22.25 n.s.
AS, ankylosing spondylitis; CCA, common carotid artery; IMTm, mean intima-media thickness; n.s., not 
significant; BULB, carotid bulb; ICA, internal carotid artery; FMD, flow-mediated dilatation.
Table III - Correlations (rho) between carotid intima-media thickness and brachial flow-mediated dilatation 
with disease activity and disability index in ankylosing spondylitis patients (n=20).
CCA-IMT BULB-IMT ICA-IMT FMD% ΔFMD
BASDAI 0.152 0.270 0.189 0.115 0.184
BASMI 0.352 0.201 0.156 0.206 0.069
BASFI 0.362 0.300 0.074 0.066 0.020
ESR 0.06 0.431* 0.272 0.052 0.439
CRP 0.205 0.237 0.003 0.110 0.083
ASDAS (ESR) 0.03 0.32 0.14 0.20 0.13
ASDAS (CRP) 0.03 0.34 0.16 0.24 0.07
CCA, common carotid artery; IMT, intima-media thickness; BULB, carotid bulb; ICA, internal carotid ar-
tery; FMD, flow-mediated dilatation; BASDAI, bath ankylosing spondylitis disease activity index; BASMI, 
bath ankylosing spondylitis metrology index; BASFI, bath ankylosing spondylitis functional index; ESR, 
eritrosedimentation rate; CRP, C-reactive protein; ASDAS, ankylosing spondylitis disease activity score. 
*P<0.05.
Table I. All patients had serum total choles-
terol, LDL, HDL, triglycerides and homo-
cysteine levels within normal ranges. IMT 
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n	 DISCUSSION
An increased mortality has been reported in 
AS patients compared to the general popu-
lation (1), and in approximately 40% of 
cases, cardiovascular disease is the leading 
cause of death (2). In particular, standard-
ized mortality ratio is 1.37 for ischemic 
heart disease, 1.25 for cerebrovascular 
diseases, 1.36 for other vascular diseases 
compared to the general population (2). In-
creased cardiovascular morbidity and mor-
tality in patients with chronic rheumatic 
diseases and the presence of an accelerated 
atherosclerotic process, related to inflam-
matory process, have been widely demon-
strated (3-5). Furthermore, IMT and FMD 
are closely related to endothelial damage 
and dysfunction, early indicators of athero-
sclerosis (18, 19). However, Mathieu et al. 
found no statistically significant differenc-
es in CCA or BULB IMT values in 60 AS 
patients and age and sex-matched controls 
(29). It should be noted that in relation to 
risk factors that could modify IMT (41-43) 
in this study there were higher levels of 
plasma cholesterol and glucose in controls 
than in patients (29). Similar results have 
also been obtained in other studies (30, 
31), which have not considered the bias of 
the presence of certain cardiovascular risk 
factors. However, when the criteria of ex-
clusion included the presence of cardiovas-
cular risk factors or cardiovascular events, 
it has been demonstrated an increased 
prevalence of subclinical atherosclerosis in 
AS (27, 28). In fact, Bodnar et al. demon-
strated increase IMT values at CCA level 
and a reduction of FMD in 43 AS patients 
compared to controls (27). Similar results 
were obtained by Hamdi et al. in a study on 
60 AS patients and controls with no history 
of risk factors or cardiovascular events. In 
this study CCA IMT values were signifi-
cantly higher in patients with AS than in 
controls (0.51 mm vs 0.39 mm, P=0.001) 
(28). Gonzales Juanatey et al. also found 
increased IMT values and prevalence of 
atherosclerotic plaques in a cohort of 64 
patients with AS with respect to controls. 
Moreover, the best predictor of carotid 
plaques in patients with AS was ESR at 
time of disease diagnosis (32). It has to be 
highlighted that these studies did not con-
sider the evaluation of single carotid seg-
ments. This aspect is particularly important 
in relation to the evidence that the classic 
risk factors for atherosclerosis may have a 
different impact on the intima-media thick-
ness in relation to anatomical sites (33). 
Moreover, the progression of IMT is not 
homogeneous in the different arterial seg-
ments, and could be greater at BULB and 
ICA level (34). In our study, the evidence 
of IMT values significantly increased in 
patients with AS compared to controls only 
at carotid bulb segment confirms that the 
evaluation of this district is essential in the 
study of subclinical atherosclerosis. In fact, 
in this anatomical site, changes in endothe-
lial structure and turbulence due to carotid 
bifurcation may predispose to endothelial 
damage. With regards to the assessment of 
endothelial dysfunction by FMD, we have 
not found significant differences between 
patients and controls in the endothelium-
mediated response or correlation with dis-
ease activity and disability indices, accord-
ing to other authors (31). However, Bodnar 
found a reduction of FMD in his cohort of 
AS patients (27). Changes in FMD assess-
ment methods (for example the different 
time of occlusion) could explain the differ-
ences among these studies (44). The dis-
crepancy in IMT and FMD findings among 
different studies could also be explained 
with the presence of concomitant medica-
tions such as non steroidal anti-inflamma-
tory drugs (NSAIDs), selective inhibitors 
of cyclooxygenase type 2 (coxibs) and 
TNFα inhibitors commonly used in AS. In 
fact, NSAIDs and coxibs may be able to 
alter the vasodilator response endothelium 
mediated by production of vasoactive sub-
stances (45), while anti-TNFα drugs can 
induce significant changes in carotid ath-
erosclerotic progression and improve endo-
thelial function (46, 47). However, it should 
be noted that in our study AS patients were 
not treated with anti-TNFα drugs and dis-
continued NSAIDs or coxibs at least 24 h 
before the test. Moreover, inflammatory 
burden in AS patients is often less severe 
than in psoriatic arthritis or rheumatoid ar-
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thritis patients (48). This may explain, at 
least in part, why endothelial dysfunction 
was observed in patients with psoriatic ar-
thritis and not in this smaller cohort of AS 
patients.
In our study we also found a correlation 
between carotid bulb IMT and ESR values, 
suggesting that inflammation in AS may ac-
celerate atherosclerotic process. It was also 
highlighted an inverse correlation between 
BASDAI and CRP with plasma concentra-
tions of HDL in support of the hypothesis 
that the disease activity may influence lipid 
balance in pro-atherogenic profile, also in 
patients with AS, as observed in rheuma-
toid arthritis (49). 
In conclusion, our results showed that, in 
the absence of cardiovascular risk factors, 
there is an alteration of carotid wall mor-
phology at bulb segment in AS patients, 
probably due to the presence of a chron-
ic inflammatory process, typical of AS. 
These results suggest that, in the study of 
subclinical atherosclerosis, morphological 
evaluation of the carotid wall should be 
performed in all arterial segments (CCA, 
BULB and ICA). We need further longi-
tudinal studies of larger series of patients 
with AS to define the predictive value of 
endothelial dysfunction to development of 
cardiovascular events. 
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